MX2017000141A - Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas. - Google Patents

Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.

Info

Publication number
MX2017000141A
MX2017000141A MX2017000141A MX2017000141A MX2017000141A MX 2017000141 A MX2017000141 A MX 2017000141A MX 2017000141 A MX2017000141 A MX 2017000141A MX 2017000141 A MX2017000141 A MX 2017000141A MX 2017000141 A MX2017000141 A MX 2017000141A
Authority
MX
Mexico
Prior art keywords
making
methods
same
targeted therapeutic
therapeutic nanoparticles
Prior art date
Application number
MX2017000141A
Other languages
English (en)
Inventor
Hong Wang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017000141A publication Critical patent/MX2017000141A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen nanopartículas poliméricas que incluyen un agente terapéutico, y métodos para elaborar y utilizar tales nanopartículas terapéuticas; en algunas modalidades, las nanopartículas contempladas pueden incluir un excipiente.
MX2017000141A 2014-07-03 2015-07-02 Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas. MX2017000141A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020609P 2014-07-03 2014-07-03
PCT/US2015/038963 WO2016004290A1 (en) 2014-07-03 2015-07-02 Targeted therapeutic nanoparticles and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2017000141A true MX2017000141A (es) 2017-04-25

Family

ID=53724455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000141A MX2017000141A (es) 2014-07-03 2015-07-02 Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.

Country Status (12)

Country Link
US (3) US10182996B2 (es)
EP (1) EP3164119B1 (es)
KR (2) KR20190018052A (es)
CN (1) CN107072962A (es)
AU (1) AU2015284017A1 (es)
BR (1) BR112017000022A2 (es)
CA (1) CA2953996A1 (es)
ES (1) ES2847894T3 (es)
IL (1) IL249894A0 (es)
MX (1) MX2017000141A (es)
RU (1) RU2706791C2 (es)
WO (1) WO2016004290A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018133578A (ru) * 2016-03-25 2020-04-27 Пфайзер Инк. Стабильные составы для лиофилизации терапевтических частиц
WO2018073740A1 (en) * 2016-10-20 2018-04-26 Pfizer Inc. Therapeutic polymeric nanoparticles comprising lipids and methods of making and using same
WO2018141810A1 (en) * 2017-01-31 2018-08-09 Alf Lamprecht Use of nanoparticles for immunotherapy
US10369230B2 (en) 2017-04-06 2019-08-06 National Guard Health Affairs Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy
WO2019057113A1 (en) * 2017-09-22 2019-03-28 Jingjie Ptm Biolab (Hangzhou) Co., Ltd. CAPECITABINE POLYMER-LIPID HYBRID NANOPARTICLES USING MICROMELIN AND AMPHIPHILIC CAPECITABINE PROPERTIES
WO2024053862A1 (ko) * 2022-09-08 2024-03-14 주식회사 삼양홀딩스 약물 함유 나노입자 제조용 키트 및 약물전달용 나노입자 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
CN101583379B (zh) * 2006-10-05 2013-04-03 约翰斯霍普金斯大学 使用优良聚合物纳米粒子的水溶性差药物的水可分散性口服，肠胃外和局部制剂
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US20090148384A1 (en) * 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
ES2721850T3 (es) * 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
EA021422B1 (ru) 2008-06-16 2015-06-30 Бинд Терапьютикс, Инк. Полимерные наночастицы, содержащие терапевтическое средство, и способ их получения
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
EP2306829B1 (en) * 2008-07-01 2017-01-04 University of Chicago Particles containing a peripheral opioid receptor antagonist
CN102740836A (zh) * 2009-04-24 2012-10-17 伊休蒂卡有限公司 用于制备商品化纳米颗粒和微粒粉末的方法
US9295649B2 (en) * 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2012101242A1 (en) * 2011-01-27 2012-08-02 Capsulution Pharma Ag Novel pharmaceutical suspension for parenteral application
US20130149381A1 (en) * 2011-12-08 2013-06-13 Centro De Investigacion En Quimica Aplicada Absorption method for entrapment of drugs in polymeric nanoparticles
EP2790733B1 (en) * 2011-12-14 2019-10-30 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
EP2804632B1 (en) * 2012-01-19 2019-09-18 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CN103585634A (zh) * 2013-10-22 2014-02-19 汤民 一种多西他赛聚合物纳米药物制剂及其制备方法

Also Published As

Publication number Publication date
ES2847894T3 (es) 2021-08-04
US10182996B2 (en) 2019-01-22
CN107072962A (zh) 2017-08-18
AU2015284017A1 (en) 2017-01-05
EP3164119B1 (en) 2020-11-18
WO2016004290A1 (en) 2016-01-07
IL249894A0 (en) 2017-03-30
BR112017000022A2 (pt) 2017-11-07
RU2016149734A (ru) 2018-08-06
KR20170023173A (ko) 2017-03-02
EP3164119A1 (en) 2017-05-10
KR20190018052A (ko) 2019-02-20
US20170128380A1 (en) 2017-05-11
CA2953996A1 (en) 2016-01-07
US20200306201A1 (en) 2020-10-01
RU2706791C2 (ru) 2019-11-21
US20190151251A1 (en) 2019-05-23
RU2016149734A3 (es) 2018-08-06

Similar Documents

Publication Publication Date Title
IL249370A0 (en) Fap-enabled medical substances and related uses
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
HK1251183A1 (zh) 生物綴合物及其用途
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
AU362319S (en) Pet treat
GB2541571A (en) Pharmaceutical compositions
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
GB2587284B (en) Well ranging apparatus. methods, and systems
IL248196A0 (en) Polymer template and preparations for it
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
IL271728A (en) Materials, uses and treatment methods
AU2015315168A8 (en) Targeted mutagenesis in spirulina
PH12017500602A1 (en) Methods for treating ocular conditions
AU359166S (en) Earplug
AU359108S (en) Earplug
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
IL250844A0 (en) Medical nanoparticles and related preparations, methods and systems
PT3294361T (pt) Um stent ureteral, métodos e utilizações dos mesmos
AU359167S (en) Earplug
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
GB201715724D0 (en) Devices,and methods and uses relating thereto
MX2017001929A (es) Activacion del factor x.